Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.36M | 48.17M | 46.83M | 44.62M | 41.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.36M | 48.17M | 46.83M | 44.62M | 41.40M |
| Cost of Revenue | 16.29M | 16.57M | 16.29M | 15.71M | 15.04M |
| Gross Profit | 29.07M | 31.60M | 30.54M | 28.91M | 26.36M |
| SG&A Expenses | 21.99M | 21.45M | 21.14M | 20.13M | 19.35M |
| Depreciation & Amortization | -- | -- | -- | 27.00K | 226.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.02M | 38.73M | 38.11M | 36.50M | 35.20M |
| Operating Income | 6.34M | 9.44M | 8.72M | 8.12M | 6.20M |
| Income Before Tax | 5.47M | 8.52M | 7.57M | 6.67M | 4.78M |
| Income Tax Expenses | 14.00K | 18.00K | 4.00K | 17.00K | 17.00K |
| Earnings from Continuing Operations | 5.46 | 8.50 | 7.56 | 6.65 | 4.76 |
| Earnings from Discontinued Operations | -280.00K | -247.00K | -244.00K | -185.00K | -189.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.18M | 8.26M | 7.32M | 6.47M | 4.57M |
| EBIT | 6.34M | 9.44M | 8.72M | 8.12M | 6.20M |
| EBITDA | 6.72M | 9.78M | 9.02M | 8.40M | 6.63M |
| EPS Basic | 1.07 | 1.77 | 1.56 | 1.48 | 1.05 |
| Normalized Basic EPS | 0.78 | 1.21 | 1.08 | 0.96 | 0.69 |
| EPS Diluted | 0.25 | 0.95 | 1.06 | 1.48 | 1.04 |
| Normalized Diluted EPS | 0.19 | 0.63 | 0.70 | 0.95 | 0.68 |
| Average Basic Shares Outstanding | 17.64M | 17.60M | 17.55M | 17.47M | 17.40M |
| Average Diluted Shares Outstanding | 86.27M | 86.25M | 62.93M | 17.55M | 17.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |